Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gerda Leitner is active.

Publication


Featured researches published by Gerda Leitner.


Vox Sanguinis | 2006

Platelet content and growth factor release in platelet-rich plasma: a comparison of four different systems

Gerda Leitner; R. Gruber; J. Neumüller; A. Wagner; P. Kloimstein; Paul Höcker; G. F. Körmöczi; C. Buchta

Background  Different systems for preparation of platelet‐rich plasma are commercially available, but data for comparison of these systems have not been published so far.


Journal of Pediatric Hematology Oncology | 2009

Granulocyte transfusions in children and young adults: does the dose matter?

Markus G. Seidel; Milen Minkov; Volker Witt; Susanne Matthes-Martin; Ulrike Pötschger; Nina Worel; Gerda Leitner; Jan Stary; Helmut Gadner; Christina Peters

Background Granulocyte transfusions (GTs) may increase the absolute neutrophil count (ANC) before hematopoietic regeneration in neutropenic patients after chemotherapy or hematopoietic stem cell transplantation and support anti-infective immunity. Procedure We assessed efficacy and tolerability of 778 GTs in 70 treatment episodes of 49 children and 10 young adults [median age 6.28 y (range: 0.13 to 17.7 y) and 21 y (18.0 to 28.0), respectively] suffering from bacterial (n=55) and/or fungal (n=31) infections during neutropenia owing to conventional chemotherapy (n=14), hematopoietic stem cell transplantation conditioning (n=44), or the underlying disease (n=1). We analyzed the impact of body weight, organ dysfunction, neutrophil dose on ANC increment, infection elimination, and survival. Results The median day-5 ANC increment was 1460/μL, correlating to the administered dose. However, 28-day survival did not correlate to the neutrophil dose nor to the ANC increment, potentially owing to the high number of neutrophils transfused to all patients (median >6×109/kg within 5 d). The 28-day survival probability of the total patient cohort was 0.72±0.06 and the 100-day survival was 0.52±0.07. Adverse reactions were rare including fever (≤World Health Organization grade III, 14%), chills (3%), and mild pulmonary complications (1%). Conclusions These data corroborate the empirical evidence that GT with sufficient cell doses and rapid availability are a feasible, well-tolerated supplemental means to fight severe infections in neutropenic patients.


Transfusion | 2007

Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO‐mismatched allogeneic peripheral blood progenitor cell transplantation after reduced‐intensity conditioning

Nina Worel; Hildegard Greinix; Volker Supper; Gerda Leitner; Margit Mitterbauer; Werner Rabitsch; Gottfried Fischer; Agathe Rosenmayr; Paul Höcker; Peter Kalhs

BACKGROUND: Delayed severe immune hemolysis due to donor‐derived passenger lymphocytes is observed in minor and/or bidirectional ABO‐mismatched transplants, especially after reduced‐intensity conditioning (RIC). The incidence is reported in up to 30 percent of patients and can result in multiorgan failure (MOF) and death.


Transfusion | 1998

Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis

M. Dettke; M. Hlousek; M. Kurz; Gerda Leitner; K. Rosskopf; G. Stiegler; P. Stohlawetz; Nina Worel; Paul Höcker; Simon Panzer

BACKGROUND: Thrombopoietin (TPO) is a key cytokine involved in the regulation of megakaryocytopoiesis and platelet production. The aim of the present study was to test whether platelet donation is associated with changes in the serum TPO levels in healthy donors undergoing plateletpheresis.


Malaria Journal | 2012

Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: a retrospective cohort study.

Lorenz Auer-Hackenberg; Thomas Staudinger; Andja Bojic; Gottfried J. Locker; Gerda Leitner; Wolfgang Graninger; Stefan Winkler; Michael Ramharter; Nina Worel

BackgroundSevere falciparum malaria is associated with considerable rates of mortality, despite the administration of appropriate anti-malarial treatment. Since overall survival is associated with total parasite biomass, blood exchange transfusion has been proposed as a potential method to rapidly reduce peripheral parasitaemia. However, current evidence suggests that this treatment modality may not improve outcome. Automated red blood cell exchange (also referred to as “erythrocytapheresis”) has been advocated as an alternative method to rapidly remove parasites from circulating blood without affecting patients’ volume and electrolyte status. However, only limited evidence from case reports and case series is available for this adjunctive treatment. This retrospective cohort study describes the use of automated red blood cell exchange for the treatment of severe malaria at the Medical University of Vienna.MethodsEpidemiologic data for imported malaria cases in Austria are reported and data of patients treated for malaria at the General Hospital/Medical University of Vienna were extracted from electronic hospital records.ResultsBetween 2000 and 2010, 146 patients were hospitalized at the Medical University of Vienna due to malaria and 16 of those were classified as severe malaria cases. Eleven patients of this cohort were potentially eligible for an adjunctive treatment with automated red blood cell exchange. Five patients eventually underwent this procedure within a period of seven hours (range: 3–19 hours) after hospital admission. Six patients did not undergo this adjunctive treatment following the decision of the treating physician. The procedure was well tolerated in all cases and rapid reduction in parasite counts was achieved without occurrence of haemodynamic complications. One patient died within seven days, whereas four patients survived without any sequelae.Discussion and conclusionAutomated red blood cell exchange was a safe and efficient procedure to rapidly clear peripheral parasitaemia. Whether the fast reduction in parasite biomass may ultimately improve patient survival remains however unclear. Randomized controlled trials are needed to conclusively appreciate the value of this adjunctive treatment.


Transfusion | 2013

Recovery, safety, and tolerability of a solvent/detergent‐treated and prion‐safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers

Petra Jilma-Stohlawetz; Friedrich W. Kursten; Michaela Horvath; Gerda Leitner; Jana List; Jana Marcek; Peter Quehenberger; Michael Schwameis; Johann Bartko; Ulla Derhaschnig; Bernd Jilma

Octaplas LG is a prion‐depleted version of a previous generation product called Octaplas S/D. We compared the recovery, safety, and tolerability of these two pharmaceutical‐grade plasmas.


World Journal of Gastrointestinal Pharmacology and Therapeutics | 2016

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults

Gerda Leitner; Harald Vogelsang

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory conditions mainly of the colon and small intestine. Crohns disease (CD) and ulcerative colitis (UC) are the most frequent types of IBD. IBD is a complex disease which arises as a result of the interaction of environmental, genetic and immunological factors. It is increasingly thought that alterations of immunological reactions of the patients to their own enterable bacteria (microfilm) may contribute to inflammation. It is characterized by mucosal and sub mucosal inflammation, perpetuated by infiltration of activated leukocytes. CD may affect the whole gastrointestinal tract while UC only attacks the large intestine. The therapeutic goal is to achieve a steroid-free long lasting remission in both entities. UC has the possibility to be cured by a total colectomy, while CD never can be cured by any operation. A lifelong intake of drugs is mostly necessary and essential. Medical treatment of IBD has to be individualized to each patient and usually starts with anti-inflammatory drugs. The choice what kind of drugs and what route administered (oral, rectal, intravenous) depends on factors including the type, the localization, and severity of the patients disease. IBD may require immune-suppression to control symptoms such as prednisolone, thiopurines, calcineurin or sometimes folic acid inhibitors or biologics like TNF-α inhibitors or anti-integrin antibodies. For both types of disease (CD, UC) the same drugs are available but they differ in their preference in efficacy between CD and UC as 5-aminosalicylic acid for UC or budesonide for ileocecal CD. As therapeutic alternative the main mediators of the disease, namely the activated pro-inflammatory cytokine producing leukocytes can be selectively removed via two apheresis systems (Adacolumn and Cellsorba) in steroid-refractory or dependent cases. Extracorporeal photopheresis results in an increase of regulatory B cells, regulatory CD8(+) T cells and T-regs Type 1. Both types of apheresis were able to induce clinical remission and mucosal healing accompanied by tapering of steroids.


Biology of Blood and Marrow Transplantation | 2015

Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues

Nina Worel; Andreas Buser; Hildegard Greinix; Hans Hägglund; Willis H. Navarro; Michael A. Pulsipher; Grazia Nicoloso-de Faveri; Mats Bengtsson; Annelies Billen; German Espino; M Fechter; Valeria Giudice; Kristina Hölig; Heiwa Kanamori; Yoshihisa Kodera; Gerda Leitner; Tanja Netelenbos; Dietger Niederwieser; Suzanna M. van Walraven; Vanderson Rocha; Tigran Torosian; Carmen Vergueiro; Daniel J. Weisdorf; Hiromasa Yabe; Jörg Halter

The number of allogeneic hematopoietic stem cell (HSC) transplants performed globally each year continues to increase. Advances in HLA typing, better supportive care, and administration of reduced-intensity conditioning regimens allow treatment of older patients with older sibling donors. Pretransplant donor assessment and testing are very important processes affecting the quality and safety of donation. For unrelated HSC donors detailed recommendations for health assessment have been published, allowing donation only if they are unrestrictedly healthy. Eligibility criteria for related donors are less strict and vary significantly between centers. In situations where a family donor does not meet the suitability criteria for unrelated donors, involved physicians often struggle with the decision whether the matched relative is suitable for donation or not. On behalf of the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues, we intended to develop a consensus document with recommendations for donor workup and final clearance of family donors who would not be able to serve as unrelated donors because of their age or pre-existing diseases. This article covers different topics intending to support decision-making, with the goal of minimizing medical risk to the donor and protection of the recipient from transmissible diseases.


Transfusion Medicine and Hemotherapy | 2013

Monitoring of Platelet Activation in Platelet Concentrates Using Transmission Electron Microscopy

Josef Neumüller; Claudia Meisslitzer-Ruppitsch; Adolf Ellinger; Margit Pavelka; Christof Jungbauer; Renate Renz; Gerda Leitner; Thomas Wagner

Objective: The quality of platelet concentrates (PC) is important for the in vivo recovery of thrombostasis in patients suffering from bleeding disorders and in tumor patients after chemotherapy. In this respect, activated platelets (PLT) cannot display their full functionality in the recipient and even can cause adverse effects. Therefore, we developed a transmission electron microscopy (TEM) method for quality assessment of PC. Methods: Score values taken from panorama TEM images describe the progress of PLT activation. To exemplify this method, i) 19 apheresis PC isolated with the Baxter Amicus system (BA) were compared with 14 PC obtained from pooled buffy coats (BC). ii) The score values of 33 PC derived from BA as well from BC were compared with flow-cytometric CD62P determinations by cross correlation. iii) Changes in the score value profiles during storage of a single pathogen-reduced BA PC were monitored over a period of 7 days. Results: The TEM evaluation described allows for demonstrating particular PLT activation stages. i) Significant differences between the percentages of the score values 0, 1 and 2 could be demonstrated in both processing groups. No significant differences were found comparing these two groups. ii) A weak correlation could be shown when comparing the percentages of score values 2 plus 3 with the percentage of CD62P-positive PLT. iii) The pathogen reduction affected slightly the score profiles during storage due to an increase of dead PLT. Conclusion: Our investigations demonstrate the unique detailed quality information of PC obtained by the TEM method. This method can be performed in every routine electron microscopy laboratory.


European Journal of Haematology | 2004

Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.

Werner Rabitsch; Erika Prinz; Jutta Ackermann; Stefan Wöhrer; Hannes Kaufmann; Sonja Seidl; Felix Keil; Peter Kalhs; Hildegard Greinix; Heinz Gisslinger; Gerda Leitner; Johannes Drach

Objectives:  Allogeneic transplantation may offer a curative approach to multiple myeloma (MM). We retrospectively analyzed the outcome of patients with multiple myeloma undergoing allogeneic stem celltransplantation in the context of ß2 microglobulin and chromosome 13q.

Collaboration


Dive into the Gerda Leitner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hildegard Greinix

Medical University of Graz

View shared research outputs
Top Co-Authors

Avatar

Peter Kalhs

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Werner Rabitsch

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Margit Mitterbauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Paul Höcker

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Bernd Jilma

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Michaela Horvath

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Axel Schulenburg

Medical University of Vienna

View shared research outputs
Researchain Logo
Decentralizing Knowledge